Not all tRNAs are equal: how isodecoder diversity shapes cancer

Abstract

Several tRNAs that differ only in their body sequence decode the same codon, yet their levels and behavior vary across cell types and disease contexts. In a landmark 2014 study, a mutation in the arginine isodecoder Arg-TCT-4 was linked to neurodegeneration in mice. In 2021, increased expression of the Arg-TCT family, especially Arg-TCT-4, was unexpectedly linked to oncogenic transformation in multiple cancer models. A recent publication by Kim and colleagues reports that loss of a single tRNA isodecoder, Arg-TCT-1, drives lineage plasticity and resistance to androgen receptor pathway inhibitors in prostate cancer by reducing the translation of AGA-rich mRNAs. Together, these findings raise a broader question: what do differences in isodecoder sequence actually do? They may influence tRNA processing, charging, interactions with elongation factors and the ribosome, or the modifications tRNAs receive. This commentary places the new findings in the context of prior work and considers potential mechanisms behind the functional diversity of Arg-TCT isodecoders and their role in cancer.